Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Clin Exp Metastasis. 2014 Nov 15;32(1):29–38. doi: 10.1007/s10585-014-9688-8

Figure 5. Tumor growth inhibition by T vs T-DM1.

Figure 5

Tumors were allowed to establish growth for a week after subcutaneous injection before initiation of treatment. Fifteen mice (5 mice per group) with CS xenografted tumor everexpressing HER2 (SARARK-6) were treated with a series of 5 IV injection of T-DM1 (15 mg/kg/w), T (15 mg/kg/w) and vehicle, respectively. T-DM1 treatment resulted in a dramatic reduction of tumors volumes and complete disappearance of established disease when compared to T and to vehicle group (P=0.0001 and P<0.0001 respectively) (panel A). Points are mean tumor volume (cm3); bars are SEM (standard error of the mean) (n=5 mice per group). T-DM1 treatment significantly prolonged overall survival in treated group when compared to trastuzumab group and to the vehicle group (P=0.008 and P=0.0001 respectively) (panel B).